Grünenthal Agreement for Nexium, Vimovo Completed
3 December 2018 07:00 GMT Agreement with Grünenthal for rights to Nexium inEurope and Vimovo worldwide (ex-US) completed AstraZeneca has completed an agreement to divest the prescription medicine rights to Nexium(esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo(naproxen/esomeprazole) to Grünenthal. Under the terms of the agreement, AstraZeneca has received payments of $700m for Nexium and $115m for Vimovo from Grünenthal. The upfront payments, net of an appropriate derecognition of an intangible asset related to Vimovo (see below) will